Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Resverlogix Corp (RVX.TO)

Resverlogix Corp (RVX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 31,608
  • Shares Outstanding, K 287,344
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,635 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $0.00 on 11/13/25
  • Next Earnings Date 11/11/25
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1000 +10.00%
on 11/26/25
0.1500 -26.67%
on 12/03/25
+0.0150 (+15.79%)
since 11/12/25
3-Month
0.0900 +22.22%
on 11/03/25
0.1500 -26.67%
on 12/03/25
+0.0200 (+22.22%)
since 09/12/25
52-Week
0.0350 +214.29%
on 06/27/25
0.3000 -63.33%
on 07/23/25
+0.0500 (+83.33%)
since 12/12/24

Most Recent Stories

More News
Resverlogix Appoints Bradley Glass to Board of Directors

Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Company") today announces the appointment of Mr. Bradley Glass, J.D. as a member of the Company's...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders

Calgary, Alberta--(Newsfile Corp. - June 30, 2025) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta....

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024

Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart failure...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension

Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calgary,...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Stocks in play: Resverlogix Corp.

Has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 ...

RVX.TO : 0.1100 (-4.35%)
Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges

Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Updated Annual and Special Meeting of Shareholders

Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges

Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Change to Its Board of Directors

Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases...

RVX.TO : 0.1100 (-4.35%)
RVXCF : 0.0832 (-6.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone...

See More

Key Turning Points

3rd Resistance Point 0.1100
2nd Resistance Point 0.1100
1st Resistance Point 0.1100
Last Price 0.1100
1st Support Level 0.1100
2nd Support Level 0.1100
3rd Support Level 0.1100

See More

52-Week High 0.3000
Fibonacci 61.8% 0.1988
Fibonacci 50% 0.1675
Fibonacci 38.2% 0.1362
Last Price 0.1100
52-Week Low 0.0350

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar